Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arbutus Biopharma Corporation (ABUS : NSDQ)

• Company Description    Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. Number of Employees: 44

• Price / Volume Information    Yesterday's Closing Price: $3.13 Daily Weekly Monthly 20 Day Moving Average: 761,300 shares Shares Outstanding: 191.53 (millions) Market Capitalization: $599.48 (millions) Beta: 1.23 52 Week High: $4.73 52 Week Low: $2.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.85% -10.79% 12 Week -3.10% -20.35% Year To Date -4.28% -8.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 701 VETERANS CIRCLE - WARMINSTER,PA 18974 USA ph: 267-469-0914 fax: 604-419-3201 ir@arbutusbio.com http://www.arbutusbio.com

• General Corporate Information    Officers Lindsay Androski - President; Chief Executive Officer and Director David C. Hastings - Chief Financial Officer Robert Alan Beardsley - Director Joseph Bishop - Director Matthew Gline - Director Peer Information Arbutus Biopharma Corporation (CORR.) Arbutus Biopharma Corporation (RSPI) Arbutus Biopharma Corporation (CGXP) Arbutus Biopharma Corporation (BGEN) Arbutus Biopharma Corporation (GTBP) Arbutus Biopharma Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03879J100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 191.53 Most Recent Split Date: (:1) Beta: 1.23 Market Capitalization: $599.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.57 Price/Cash Flow: - Price / Sales: 93.62 EPS Growth vs. Year Ago Period: -30.00% vs. Previous Quarter: -85.71% Sales Growth vs. Year Ago Period: 15.14% vs. Previous Quarter: 12.07% ROE 03/31/25 - -75.51 12/31/24 - -63.42 09/30/24 - -68.18 ROA 03/31/25 - -55.81 12/31/24 - -48.05 09/30/24 - -51.55 Current Ratio 03/31/25 - 6.01 12/31/24 - 8.15 09/30/24 - 7.02 Quick Ratio 03/31/25 - 6.01 12/31/24 - 8.15 09/30/24 - 7.02 Operating Margin 03/31/25 - -1,196.64 12/31/24 - -1,133.85 09/30/24 - -1,137.65 Net Margin 03/31/25 - -1,196.64 12/31/24 - -1,133.85 09/30/24 - -1,137.65 Pre-Tax Margin 03/31/25 - -1,195.86 12/31/24 - -1,133.04 09/30/24 - -1,137.65 Book Value 03/31/25 - 0.41 12/31/24 - 0.51 09/30/24 - 0.56 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.04 12/31/24 - 0.03 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 3.49 12/31/24 - 2.86 09/30/24 - 0.00

Powered by Zacks Investment Research ©